Nachrichten zur Pliant Therapeutics Inc. Aktie

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share…

Lisata Therapeutics to be acquired by Kuva Labs

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other...…

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other...…

Lisata regains China rights to pancreatic cancer drug

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China’s Qilu Pharmaceutical,...…

Lisata Therapeutics to be acquired by Kuva Labs in $4-per-share cash deal

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Wednesday it has agreed to be acquired by privately held Kuva Labs in…

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...

^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH17.11.2025 / 15:19 CET/CESTDissemination of a Research, transmitted by EQS News…

Lisata Therapeutics advances certepetide, inks strategic alliances in Q3

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported financial results for the third quarter, highlighting continued clinical progress for its lead...…

Lisata Therapeutics receives 2025 BioTech Breakthrough Award for Overall BioPharma Solution of the Year

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards...…

Lisata Therapeutics reports preclinical data showing certepetide’s potential to enhance cancer drug delivery

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the...…

Lisata Therapeutics CEO discusses Catalent deal

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company’s new collaboration with Catalent, which reinforces…

Lisata Therapeutics reveals encouraging preliminary data from pancreatic cancer treatment trial

Lisata Therapeutics Inc (NASDAQ:LSTA) announced what it called “encouraging” preliminary data from the pancreatic ductal adenocarcinoma (PDAC) cohort of the...…

Lisata Therapeutics advances lead cancer drug, expects key trial results by year-end

Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates,…

Lisata Therapeutics wraps up enrollment in promising pancreatic cancer study

Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is…

Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results

Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is…

Lisata Therapeutics expands IP with key patent covering certepetide’s chemical structure and uses

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational…

Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the companys deepening collaboration with GATC Health. Mazzo…

Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer

Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the...…

Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health

Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate…

Lisata Therapeutics to lead development of opioid use disorder drug under expanded alliance

Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate…

Lisata eyes key trial milestones in 2025 as certepetide development gains momentum

Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its…

Lisata Therapeutics talks ADC breakthrough with Catalent

Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration...…

Lisata Therapeutics signs research license with Catalent

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…

Lisata Therapeutics announces research license with Catalent

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its…

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...

^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH01.04.2025 / 15:31 CET/CESTDissemination of a Research, transmitted by EQS News…

Lisata Therapeutics CEO discusses AI drug discovery collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company’s strategic collaboration with GATC Health, a leader…

Lisata Therapeutics partners with GATC Health to advance AI-driven drug development

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced the first step of an intended multi-part strategic agreement with GATC Health, a leading…

Pliant Therapeutics shares rise on better-than-expected Q4 earnings By Investing.com

Pliant Therapeutics shares rise on better-than-expected Q4 earnings…

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that…

Lisata Therapeutics CEO: 2025 to be ‘data-rich’ as certepetide trials progress

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazza told investors that he expects 2025 to be a “data-rich year” in a…

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...

^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH29.01.2025 / 09:50 CET/CESTDissemination of a Research, transmitted by EQS News…

Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones

Lisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compays pancreatic cancer trials. The company recently...…

Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trial

Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating...…

Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trial

Lisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The…

Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research ...

^Original-Research: Lisata Therapeutics Inc - from First Berlin EquityResearch GmbH21.01.2025 / 13:55 CET/CESTDissemination of a Research, transmitted by EQS News…

Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnership

Lisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead...…

Lisata Therapeutics completes patient enrollment for solid tumor cancer trial

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…

Lisata Therapeutics completes patient enrollment for CENDIFOX trial

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX…

Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solution

Lisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2…

Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year’ at 2024 BioTech Breakthrough Awards

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…

Lisata Therapeutics wins BioTech Breakthrough award

Lisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year’ at the 2024 BioTech…

Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and…

Lisata Therapeutics advances clinical trials in Q3 ahead of data-rich 2025

Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts...…

Lisata Therapeutics forms partnership for preclinical cancer immunotherapy study

Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, announced a preclinical research collaboration to explore a novel...…

Lisata Therapeutics and Valo Therapeutics partner in preclinical study on cancer immunotherapy

Lisata Therapeutics Inc (NASDAQ:LSTA), the US-based clinical-stage pharmaceutical company, and Finnish immunotherapy developer Valo Therapeutics Oy have...…

Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy

Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and…

Lisata Therapeutics strikes research partnership to investigate new treatment for endometriosis

Lisata Therapeutics Inc (NASDAQ:LSTA) has entered a research agreement with the University of Cincinnati to study the use of its cyclic…

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that…

Lisata Therapeutics begins treating second cohort of patients in bile duct cancer trial

Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has started treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort…

Lisata Therapeutics’ certepetide receives Orphan Drug Designation for cholangiocarcinoma

Lisata Therapeutics Inc (NASDAQ:LSTA) announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to…

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology…